Cadrenal Therapeutics, Inc. Common Stock (CVKD) Research

Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.

Market snapshot

Symbol
CVKD
Price
$3.50
Day change
+12.90%
Market cap
$10.0M
P/E ratio
-0.71x
52-week range
3.02-14.64
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$32.00

Peer companies

  • CollPlant Biotechnologies Ltd. (CLGN)
  • iBio, Inc. (IBIO)
  • Iterum Therapeutics plc (ITRM)
  • Klotho Neurosciences, Inc. (KLTO)
  • NeuroSense Therapeutics Ltd. (NRSN)
  • NeurAxis, Inc. (NRXS)
  • Rallybio Corporation (RLYB)
  • Sonnet BioTherapeutics Holdings, Inc. (SONN)

Recent insider activity

  • Pham Quang X — S-Sale (3613 shares) on 2026-06-16
  • Pham Quang X — S-Sale (513 shares) on 2026-06-17
  • Pham Quang X — S-Sale (1462 shares) on 2026-06-11
  • Pham Quang X — S-Sale (12996 shares) on 2026-06-12
  • Pham Quang X — S-Sale (3666 shares) on 2026-06-15

Open Cadrenal Therapeutics, Inc. Common Stock (CVKD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.